Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo Nordisk first to market with Wegovy pill Analysts see potential but question if pills are a 'game changer' Advantage for Novo could be short-lived, analysts say The approval of Novo's Wegovy pill ...

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — ...

Dec 23 (Reuters) - Novo Nordisk shares jumped ‌10% on Tuesday after the U.S. Food and ‌Drug Administration approved its weight-loss pill, giving the Danish drugmaker a competitive edge over rival Eli ...

FDA approves Novo Nordisk's weight-loss pill Novo aims to regain market share from Eli Lilly Pill broadens potential patient pool The pill is 25 milligrams of semaglutide, the same active ingredient ...

Novo Nordisk offers compelling value, trading at a 32% discount to fair value with a 3.6% yield and robust dividend growth. NVO's semaglutide-based drugs drive 74% of sales, but pipeline innovation, ...

Every chief executive dreams of it: a product so successful that it propels their company from obscurity to superstardom seemingly overnight. Among the lessons from 2025, however, is that runaway ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market. Novo Nordisk has filed a new drug application with the FDA for its ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...